Evidence map›Paper›PMID 41697118›Full record

ArticleCancer research2026

Spermine Oxidase Serves as a Key Functional Node in Microbial Dysbiosis-Induced Breast Carcinogenesis.

Deeptashree Nandi, Sheetal Parida, Deepak Verma, Jackson R Foley, Tracy Murray Stewart, Preethi Korangath, Sowjanya Thatikonda, Sumit Siddharth, Qitong Wu, Mingyang Yi and 5 more

Abstract read
In one paragraph

Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Deeptashree NandiDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-8363-9659
Sheetal ParidaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-2526-987X
Deepak VermaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4699-9609
Jackson R FoleyDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-4383-9522
Tracy Murray StewartDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-8679-6414
Preethi KorangathDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-6623-493X
Sowjanya ThatikondaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5353-7202
Sumit SiddharthDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-1902-2950
Qitong WuDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-2528-4153
Mingyang YiDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0004-7791-9952
William BishaiDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-8734-4118
Robert IvkovDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-2930-5276
Cynthia L SearsDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4059-1661
Robert A CaseroDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-5653-3306
Dipali SharmaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5032-974X

Funding

Identification of novel spermine oxidase (SMOX) inhibitors as probes for an emerging chemoprevention targetR01CA204345 · NCI · JOHNS HOPKINS UNIVERSITY · PI CASERO, ROBERT A., WOSTER, PATRICK M · 2016 to 2020
$3.4M
Evaluation of molecular determinants of racial disparity in triple-negative breast cancerR01CA204555 · NCI · JOHNS HOPKINS UNIVERSITY · PI SHARMA, DIPALI · 2017 to 2021
$1.9M
Bloomberg Philanthropies (BP) BKIBreast Cancer Research Foundation (BCRF) 90047965Commonwealth Fund (CF)Congressionally Directed Medical Research Programs (CDMRP) BC191572Congressionally Directed Medical Research Programs (CDMRP) BC210668National Cancer Institute (NCI) CA204345NCI NIH HHS R01 CA204345NCI NIH HHS R01 CA204555Panbela TherapeuticsSamuel Waxman Cancer Research Foundation (SWCRF)Sidney Kimmel Comprehensive Cancer Center (Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University) Fetting Fund for Cancer Prevention
6 · The paper itself

Abstract

Emerging evidence has highlighted the unequivocal importance of microbiota as a risk factor for breast carcinogenesis. Elucidating the underlying mechanisms is needed to identify key nodes that can be inhibited to abolish pathogenic microbe-mediated breast cancer growth and metastatic progression. Focusing on a procarcinogenic colon microbe, enterotoxigenic Bacteroides fragilis (ETBF), we uncovered the involvement of spermine oxidase (SMOX), a key enzyme of polyamine metabolism, in promoting breast tumorigenesis. Interestingly, exposure of breast cancer cells to multiple pathogenic microbes, such as Fusobacterium nucleatum and pks+Escherichia coli, and to bacterial toxins induced SMOX expression, whereas nonpathogenic bacteria exhibited no impact. Elevated levels of proinflammatory cytokines IL6 and TNFα were observed in cells exposed to multiple pathogenic bacteria, and both of these cytokines were capable of upregulating SMOX expression and activity. ETBF and B. fragilis toxin exposure led to a considerable increase in reactive oxygen species activity, induction of γH2AX foci formation, and altered expression of major DNA damage response (DDR) proteins, which were abrogated with SMOX inhibition. Pharmacologic inhibition of SMOX using MDL72527 and SXG-1 effectively impeded ETBF-induced breast carcinogenesis with long-lasting effects on tumor-dissociated cells. This work implicates the IL6/TNFα-SMOX-DDR axis as a functional mediator of the oncogenic effects of pathogenic bacteria and proposes SMOX inhibitors as an intervention strategy for treating patients with breast cancer with microbial dysbiosis. SIGNIFICANCE: Overabundance of opportunistic pathogens elevates SMOX activity via proinflammatory cytokines to accelerate breast cancer progression, which can be targeted with pharmacological inhibitors of SMOX to significantly inhibit microbiota-associated carcinogenesis.

Indexed as

Breast NeoplasmsDysbiosisOxidoreductases Acting on CH-NH Group DonorsBacterial ToxinsBacteroides fragilisCarcinogenesisCell Line, TumorFemaleFusobacterium nucleatumHumansPolyamine OxidaseReactive Oxygen SpeciesBacterial ToxinsOxidoreductases Acting on CH-NH Group DonorsPolyamine OxidaseReactive Oxygen Species

Identifiers

PMID41697118
PMCPMC12915686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.